These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 3264177

  • 21. Murine intracerebral interleukin-2 injection: pathological and immunological effects.
    Yamasaki T, Kikuchi H, Paine JT, Yamashita J, Miyatake S, Iwasaki K, Kobayashi H, Namba Y, Hanaoka M.
    J Neurosurg; 1989 Nov; 71(5 Pt 1):732-40. PubMed ID: 2809728
    [Abstract] [Full Text] [Related]

  • 22. Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration.
    Martin R, Schwuléra U, Menke G, Rudolph W, Buch K, Fasold H, Lissner R, Thrun A, Krauseneck P, Bogdahn U.
    Eur Cytokine Netw; 1992 Nov; 3(4):399-406. PubMed ID: 1421012
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic study of interleukin-2 following intravenous injection in hemodialysis patients with renal cell carcinoma.
    Kamikawa S, Sugimoto T, Asai T, Ishii K, Kim T.
    Ther Apher Dial; 2008 Feb; 12(1):67-71. PubMed ID: 18257815
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.
    Siegel JP, Lane HC, Stocks NI, Quinnan GV, Fauci AS.
    J Biol Response Mod; 1985 Dec; 4(6):596-601. PubMed ID: 3910763
    [Abstract] [Full Text] [Related]

  • 32. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation.
    Harvill ET, Fleming JM, Morrison SL.
    J Immunol; 1996 Oct 01; 157(7):3165-70. PubMed ID: 8816429
    [Abstract] [Full Text] [Related]

  • 33. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
    Alvarez HM, So OY, Hsieh S, Shinsky-Bjorde N, Ma H, Song Y, Pang Y, Marian M, Escandón E.
    Drug Metab Dispos; 2012 Feb 01; 40(2):360-73. PubMed ID: 22083830
    [Abstract] [Full Text] [Related]

  • 34. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.
    J Immunol; 1985 Oct 01; 135(4):2865-75. PubMed ID: 2993418
    [Abstract] [Full Text] [Related]

  • 35. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H, Lin KM, Chu TM.
    Cancer Res; 1990 Feb 15; 50(4):1107-12. PubMed ID: 2297759
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.